Gulf International Bank UK Ltd Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Gulf International Bank UK Ltd trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,424 shares of the biopharmaceutical company’s stock after selling 92 shares during the period. Gulf International Bank UK Ltd’s holdings in Regeneron Pharmaceuticals were worth $6,000,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SteelPeak Wealth LLC increased its position in shares of Regeneron Pharmaceuticals by 1.5% during the third quarter. SteelPeak Wealth LLC now owns 1,108 shares of the biopharmaceutical company’s stock worth $1,165,000 after acquiring an additional 16 shares during the last quarter. Oak Harvest Investment Services raised its position in shares of Regeneron Pharmaceuticals by 25.6% in the 3rd quarter. Oak Harvest Investment Services now owns 2,779 shares of the biopharmaceutical company’s stock valued at $2,921,000 after purchasing an additional 567 shares in the last quarter. Fairfield Financial Advisors LTD purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $37,000. LCM Capital Management Inc grew its holdings in Regeneron Pharmaceuticals by 4.6% during the 3rd quarter. LCM Capital Management Inc now owns 543 shares of the biopharmaceutical company’s stock worth $571,000 after acquiring an additional 24 shares in the last quarter. Finally, Focus Financial Network Inc. grew its stake in Regeneron Pharmaceuticals by 7.4% in the third quarter. Focus Financial Network Inc. now owns 538 shares of the biopharmaceutical company’s stock worth $566,000 after purchasing an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on REGN. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Bank of America reaffirmed an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Finally, Wells Fargo & Company cut their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $702.78 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The stock’s 50-day moving average is $698.57 and its two-hundred day moving average is $873.11. The firm has a market cap of $76.83 billion, a P/E ratio of 18.36, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the business earned $11.86 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.50%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.